

# Deferred Registration: Quotient Sciences Code: QSC303955

<b>Submission date</b> 07/05/2026	<b>Recruitment status</b> Not yet recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 24/06/2026	<b>Overall study status</b> Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 24/06/2026	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

## Contact information

### Type(s)

Principal investigator

### Contact name

Dr Nand Singh

### Contact details

Quotient Sciences, Mere Way, Ruddington Fields, Ruddington  
Nottingham  
United Kingdom  
NG11 6JS  
+44 (0)3303031000  
recruitment@weneedyou.co.uk

### Type(s)

Public, Scientific

### Contact name

None Skyhawk Study Doctor

### Contact details

180 3rd Ave. Sixth Floor  
Waltham  
United States of America

MA 02451  
+1-(617)-858-0041  
brian.yoon@skyhawktx.com

## Additional identifiers

**Integrated Research Application System (IRAS)**  
1013771

**Quotient Sciences code**  
QSC303955

## Study information

### Scientific Title

Deferred registration: Quotient Sciences Code: QSC303955 [Full scientific title to be added on or before the deferral expiry date]

### Study objectives

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

### Ethics approval required

Ethics approval required

### Ethics approval(s)

Submitted 27/04/2026, London – Harrow Research Ethics Committee (Health Research Authority, 2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 2071048357; harrow.rec@hra.nhs.uk), ref: 26/LO/0384

### Primary study design

Interventional

### Allocation

Non-randomized controlled trial

### Masking

Open (masking not used)

### Control

Active

### Assignment

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

### Purpose

Phase I trial in healthy volunteers

### Study type(s)

## Health condition(s) or problem(s) studied

Healthy volunteers

## Interventions

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

## Intervention Type

Drug

## Phase

Phase I

## Drug/device/biological/vaccine name(s)

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

## Primary outcome(s)

1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

## Key secondary outcome(s)

## Completion date

29/08/2026

# Eligibility

## Key inclusion criteria

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

## Healthy volunteers allowed

Yes

## Age group

Adult

## Lower age limit

18 Years

## Upper age limit

55 Years

## Sex

All

## Total final enrolment

0

### **Key exclusion criteria**

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

### **Date of first enrolment**

29/06/2026

### **Date of final enrolment**

29/08/2026

## **Locations**

### **Countries of recruitment**

United Kingdom

England

### **Study participating centre**

#### **Quotient Sciences**

Mere Way

Ruddington Fields

Ruddington

Nottingham

England

NG11 6JS

## **Sponsor information**

### **Organisation**

Skyhawk Therapeutics, Inc.

## **Funder(s)**

### **Funder type**

### **Funder Name**

Skyhawk Therapeutics, Inc.

# Results and Publications

Individual participant data (IPD) sharing plan

**IPD sharing plan summary**

Not expected to be made available